DUSP6 and hepatocellular carcinoma: After being treated with the protein synthesis inhibitor cycloheximide (CHX), western blot results revealed a shorter DUSP6 half-life in PBLD-downregulated HCC cells than the control cells, while upregulation of PBLD maintained DUSP6 expression (Fig. 3d and Supplementary Fig. 3c).